New trial
An Open-Label, Multicenter, Phase 2 Study with Safety Lead-In of Intratumoral VO Plus Pembrolizumab in Angiosarcoma
- Trial ID
- NCT06898970 on ClinicalTrials.gov
- Cancer type
- Sarcoma
- Published in
- New in Oncology - May 21, 2025
This phase 2 trial is evaluating the safety of intratumoral VO combined with pembrolizumab in patients with locally advanced or metastatic angiosarcoma who have progressed following prior immunotherapy, with an initial lead-in dose of VO preceding combination treatment.
More in sarcoma and GIST
-
Trial result · Oct 22, 2026 · NCT04514484
Nivolumab + cabozantinib shows feasible safety and prolonged disease stabilization in a small HIV-positive solid-tumor cohort -
New trial · Oct 8, 2026 · NCT07781891
Phase 2 LX-101 IGF-1R–targeted methotrexate conjugate in R/R Ewing sarcoma/DSRCT -
Trial result · Sep 10, 2026 · NCT03069469
Vimseltinib (CSF1R switch-control inhibitor) delivers 64% ORR in surgery-ineligible TGCT, including post–CSF1/CSF1R-treated patients -
New trial · Aug 13, 2026 · NCT07725380
Phase 1/2 domatinostat class I HDAC inhibitor + sirolimus mTOR inhibitor in R/R sarcoma/osteosarcoma. -
Trial result · Aug 6, 2026 · NCT05218499
Brigimadlin (MDM2–p53 antagonist) Misses PFS Endpoint vs Doxorubicin in 1L DDLPS, Despite Higher ORR